- Home
- CNF vs IGC Comparison
CNF vs IGC Comparison
Compare CNF & IGC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CNF
- IGC
- Stock Information
- Founded
- CNF 1999
- IGC 2005
- Country
- CNF China
- IGC United States
- Employees
- CNF N/A
- IGC N/A
- Industry
- CNF Finance: Consumer Services
- IGC Biotechnology: Pharmaceutical Preparations
- Sector
- CNF Finance
- IGC Health Care
- Exchange
- CNF Nasdaq
- IGC Nasdaq
- Market Cap
- CNF 35.7M
- IGC 39.8M
- IPO Year
- CNF 2018
- IGC N/A
- Fundamental
- Price
- CNF $3.05
- IGC $0.42
- Analyst Decision
- CNF
- IGC Strong Buy
- Analyst Count
- CNF 0
- IGC 2
- Target Price
- CNF N/A
- IGC $4.00
- AVG Volume (30 Days)
- CNF 97.1K
- IGC 1.4M
- Earning Date
- CNF 08-28-2025
- IGC 11-11-2025
- Dividend Yield
- CNF N/A
- IGC N/A
- EPS Growth
- CNF N/A
- IGC N/A
- EPS
- CNF N/A
- IGC N/A
- Revenue
- CNF $50,241,013.00
- IGC $1,327,000.00
- Revenue This Year
- CNF $252.34
- IGC $15.26
- Revenue Next Year
- CNF N/A
- IGC $3.41
- P/E Ratio
- CNF N/A
- IGC N/A
- Revenue Growth
- CNF N/A
- IGC 24.95
- 52 Week Low
- CNF $2.36
- IGC $0.25
- 52 Week High
- CNF $28.40
- IGC $0.50
- Technical
- Relative Strength Index (RSI)
- CNF 37.38
- IGC 55.54
- Support Level
- CNF $2.85
- IGC $0.38
- Resistance Level
- CNF $3.59
- IGC $0.47
- Average True Range (ATR)
- CNF 0.95
- IGC 0.04
- MACD
- CNF -0.02
- IGC -0.00
- Stochastic Oscillator
- CNF 17.74
- IGC 32.50
About CNF CNFinance Holdings Limited each representing twenty (20)
CNFinance Holdings Ltd is an equity loan service provider. It focuses on the development of small and micro-enterprises. It generates revenue in the form of interest and financing service fees on loans and interest on deposits with banks. Its primary target borrower segment is MSE owners who own real properties in Tier 1 and Tier 2 cities in China. Geographically, it has an operation in PRC.
About IGC IGC Pharma Inc.
IGC Pharma Inc develops cannabinoid-based formulations for treating diseases and conditions, including, but not limited to, Alzheimer's disease, period cramps, premenstrual syndrome, and chronic pain. The company has investigational drug assets targeting Alzheimer's disease, IGC-AD1, IGC-M3, IGC-1C, and TGR-63, which have demonstrated in Alzheimer's cell lines the potential to be effective in suppressing or ameliorating key hallmarks of Alzheimer's disease, such as plaques or tangles.